Project Grant R44GM153078

Award Date 5/6/24
Completion Date 4/30/26
Dollars Obligated $5.6M
Federal Grant Program
93.859
Assistance Type
Project Grant
Place of Performance
Branford, CT 06405, USA
Similar Awards
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training Program (CFDA 93.859) provides $350,000 to Electronic Biosciences, Inc., a small biotechnology company, to develop a novel technology for high-accuracy sequencing of the RNA modifications pseudouridine (Ps) and N6-methyladenosine (M6A). The project aims to merge the company's nanopore-based sequencing platform with innovative bisulfite adduct methodology...
The National Institute of General Medical Sciences (NIGMS) awarded a $305,892 Project Grant under the Biomedical Research and Research Training Program (CFDA 93.859) to Dotquant LLC, a for-profit biotechnology research and development company. The purpose of this award is to develop a new in vitro transcription kit that combines the high efficiency and low cost of wild-type T7 RNA polymerase with the tolerance of modified nucleotides of mutant T7 RNA polymerases. This innovative kit will...
This Project Grant award, valued at $905,853, was provided by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training Program (CFDA 93.859). The award supports the development of innovative technologies by Molecular Instruments, Inc., a for-profit manufacturer of scientific instruments and probes, to enable automated, ultrasensitive, and multiplex imaging of RNA and proteins in biological samples. Specifically, the funding will enable the...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) provides $700,000 in funding to Mirimus, Inc. to support the creation of next-generation RNA interference (RNAi) therapeutics and an in vivo model for evaluating their efficacy and biodistribution. The key products and services to be delivered under this award include: 1) Generating optimized small interfering RNAs (siRNAs) and...
This Project Grant award from the National Human Genome Research Institute (NHGRI), under the Human Genome Research program (CFDA 93.172), is for the development of an exhaustive de novo RNA sequencing method using next-generation mass spectrometry (NGMS-seq). The $215,088 award to Directseq Biosciences, Inc. aims to 1) further advance NGMS-seq to completely sequence all RNA species in a sample, including comprehensive identification and quantification of RNA modifications, and 2) test the...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award to Multitarga LLC, a small business located in Woodbridge, CT, provides $304,995 to develop an "Adaptive Multi-Targeted Priming for Host-Pathogen Transcriptomics" technology. The goal is to enhance the sensitivity and specificity of RNA sequencing assays to better detect low-abundance pathogen transcripts in complex host-pathogen samples. The project will produce an...
This $3,000,000 project grant, awarded by the National Science Foundation (NSF) under the Engineering (CFDA 47.041) program, aims to solve the long-standing challenge of developing self-amplifying ribonucleic acid (SARNA) technologies. The project, led by Trustees of Boston University, a private non-profit research university, will: Synthesize a diverse library of modified nucleoside triphosphates (ModNTPs) and use them to produce modified SARNA with extended cellular half-life. Evaluate the...
The National Institute of General Medical Sciences (NIGMS) awarded a $307,257 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to SXRNA Technologies, Inc. The funding supports the development of SXRNA-SELECT, a rapid cloning technology that aims to decrease the time required to clone mammalian cells and increase protein yields for biotherapeutic production. Through this Phase I effort, SXRNA Technologies, in collaboration with the University at Albany-SUNY,...
This Project Grant award from the National Human Genome Research Institute (NHGRI), under the Human Genome Research program (CFDA 93.172), provides $406,500 to Directseq Biosciences, Inc. to advance high-throughput mass spectrometry-based sequencing (NGMS-SEQ) methods for direct sequencing and quantitative mapping of RNA modifications. The key objectives are to: 1) enhance NGMS-SEQ techniques to enable high-throughput direct sequencing of various tRNA samples, including physiologically...
This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the "Discovery and Applied Research for Technological Innovations to Improve Human Health" (CFDA 93.286) program, provides $540,524 to the University of Massachusetts Medical School (UMass Medical) to develop an enhanced RNA switch technology for precise temporal and dose control of in vivo gene therapies. The key objectives are to: (I) optimize an ultra-efficient RNA switch...

DEVELOP, OPTIMIZE AND COMMERCIALIZE ULTRAMARATHONRT: A NEW ENZYME FOR UNBIASED TRANSCRIPTOMIC AND EPITRANSCRIPTOMIC CHARACTERIZATION OF RNAS REGARDLESS OF LENGTH OR COMPOSITION. - SUMMARY RNA IS THE CENTRAL BIOMOLECULE OF LIFE, AS IT CONNECTS THE SEQUENCE OF DNA TO THE PRODUCTION OF PROTEINS, AND SERVES AS A STRUCTURAL BUILDING BLOCK FOR CRITICAL COMPONENTS WITHIN THE CELL. DESPITE THE IMPORTANCE OF DETECTING, QUANTIFYING AND SEQUENCING RNAS IN ORDER TO EXPLOIT THEIR ROLES IN BIOLOGY AND MEDICINE, THE FIELD OF RNA RESEARCH REMAINS LIMITED BY THE TOOLS AVAILABLE FOR MONITORING AND MANIPULATING RNA. AN ENZYME CALLED REVERSE TRANSCRIPTASE (RT) IS THE MOST FOUNDATIONAL TOOL FOR CONVERTING RNA INTO CDNA, ENABLING SENSITIVE DETECTION AND RNA SEQUENCING. HOWEVER, EXISTING, COMMERCIALLY AVAILABLE RTS HAVE SIGNIFICANT DEFICENCIES THAT LIMIT OUR ABILITY TO FULLY EXPLOIT THEM AS ENGINES FOR ANALYSIS AND SEQUENCING. THIS PROBLEM HAS NOW BEEN SOLVED WITH THE DISCOVERY OF POWERFUL NEW ULTRAPROCESSIVE RTS, MARATHONRT (MRT) AND ULTRAMARATHONRT (UMRT). DISCOVERED BY THE PYLE LAB AT YALE UNIVERSITY, MRT IS AN EXCEPTIONALLY PROCESSIVE RT THAT COPIES KILOBASE-LENGTH RNAS (SUCH AS THE 30KB CORONAVIRUS GENOME) IN A SINGLE PASS WITHOUT INHIBITION BY SECONDARY STRUCTURES OR REPEATS WITHIN AN RNA TEMPLATE. UNLIKE OTHER RTS, PERFORMANCE IS MAINTAINED AT AMBIENT TEMPERATURES, WHICH ELIMINATES RNA DEGRADATION AND ENABLES REAGENT KITS THAT CAN BE DEPLOYED WITHOUT REFRIGERATION. FOR COMMERCIALIZATION, THE HIGH-PERFORMANCE VERSION, UMRT, WILL BE DEVELOPED, OPTIMIZED AND INCORPORATED INTO A SUITE OF COMMERCIAL PRODUCTS FOR MASS DISTRIBUTION. THIS SBIR GRANT IS INTENDED TO FUND THE WORK NECESSARY TO CREATE, DEVELOP, TEST AND OPTIMIZE THESE UMRT PRODUCTS FOR THE MOST COMMON RT-PCR, QRT-PCR AND SEQUENCING APPLICATIONS. THIS GRANT WILL TRANSLATE AN INNOVATIVE SCIENTIFIC DISCOVERY INTO FULL-FLEDGED COMMERCIAL PRODUCTS THAT WILL SIGNIFICANTLY IMPROVE RESEARCH AND CLINICAL PRACTICE, UNDERSCORING THE ECONOMIC POWER OF SUPERIOR ENZYMATIC 'HARDWARE.' WE WILL PRODUCE A FAMILY OF PRODUCTS THAT BOOSTS THE SENSITIVITY OF RT-PCR AND RNA SEQUENCING BY EMPLOYING A POWERFUL NEW GENERATION OF REVERSE-TRANSCRIPTASE (RT) ENZYMES. HISTORY HAS SHOWN THAT INNOVATION TYPICALLY FOLLOWS THE CREATION OF MORE POWERFUL SCIENTIFIC TOOLS, SUCH AS THE CREATION OF THE COMMERCIAL BIOTECHNOLOGY INDUSTRY THAT FOLLOWED THE DEVELOPMENT OF RECOMBINANT DNA TECHNOLOGY IN THE 1970S, OR THE EMERGING FIELD OF GENE EDITING THERAPEUTICS FOLLOWING THE DISCOVERY OF CRISPR ENZYMES. THE INTRODUCTION OF UMRT PRODUCTS IS A SIMILAR WATERSHED MOMENT AS THE SCIENTIFIC COMMUNITY WILL, FOR THE FIRST TIME, BE ABLE TO READ AND DETECT VARIATION WITHIN WHOLE TRANSCRIPTOMES, REVEALING PREVIOUSLY 'INVISIBLE' INFORMATION THAT IS CRITICAL FOR UNDERSTANDING ALL LAYERS OF BIOLOGICAL FUNCTION, FROM PATIENTS TO SINGLE CELLS.

Posted 4/29/24, 12:00 AM